{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:42:02Z","timestamp":1788381722998,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13023-015-0344-4","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T12:53:20Z","timestamp":1444222400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships"],"prefix":"10.1186","volume":"10","author":[{"given":"Nouriya A.","family":"Al-Sannaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah S.","family":"Barbouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Benhayoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Goizet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Guelbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Obikawa","family":"Kyosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanika","family":"Phornphutkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Reig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pleat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Fallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Ivanovska Holder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,7]]},"reference":[{"issue":"10","key":"344_CR1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/gim.2014.25","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 2014;16(10):759\u201365. doi: 10.1038\/gim.2014.25 .","journal-title":"Genet Med"},{"issue":"1","key":"344_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","volume":"123","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123(1):19\u201329. doi: 10.1542\/peds.2008-0416 .","journal-title":"Pediatrics"},{"issue":"1","key":"344_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229\u201340. doi: 10.1542\/peds.2007-3847 .","journal-title":"Pediatrics"},{"issue":"3","key":"344_CR4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182\u20138. doi: 10.1056\/NEJM200101183440304 .","journal-title":"N Engl J Med"},{"issue":"1","key":"344_CR5","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120(1):e37\u201346. doi: 10.1542\/peds.2006-2156 .","journal-title":"Pediatrics"},{"issue":"5","key":"344_CR6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581\u20138. doi: 10.1016\/j.jpeds.2004.01.046 .","journal-title":"J Pediatr"},{"issue":"2","key":"344_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111(2):63\u201372. doi: 10.1016\/j.ymgme.2013.11.015 .","journal-title":"Mol Genet Metab"},{"issue":"2","key":"344_CR8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90(2):171\u201380. doi: 10.1016\/j.ymgme.2006.08.007 .","journal-title":"Mol Genet Metab"},{"issue":"1","key":"344_CR9","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1542\/peds.2009-1728","volume":"125","author":"O Gabrielli","year":"2009","unstructured":"Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2009;125(1):e183\u20137. doi: 10.1542\/peds.2009-1728 .","journal-title":"Pediatrics"},{"issue":"3","key":"344_CR10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","volume":"109","author":"S Laraway","year":"2013","unstructured":"Laraway S, Breen C, Mercer J, Jones S, Wraith JE. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Mol Genet Metab. 2013;109(3):315\u20136. doi: 10.1016\/j.ymgme.2013.04.023 .","journal-title":"Mol Genet Metab"},{"issue":"4","key":"344_CR11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymgme.2011.08.029","volume":"104","author":"M Furujo","year":"2011","unstructured":"Furujo M, Kubo T, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab. 2011;104(4):597\u2013602. doi: 10.1016\/j.ymgme.2011.08.029 .","journal-title":"Mol Genet Metab"},{"key":"344_CR12","unstructured":"Inwood A, Cole G, Askin G, et al. editors. Sibling Comparison Study of 10 Years of Enzyme Replacement Therapy for Mucopolysaccharidosis Type VI Starting at 3.5 Years and 8 Weeks of Age. 13th International Symposium on Mucopolysaccharidoses and Related Diseases 2014; Brazil. J Inborn Errors Metab Screen. 2014;2:68"},{"issue":"5","key":"344_CR13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","volume":"77","author":"JJ McGill","year":"2009","unstructured":"McGill JJ, Inwood AC, Coman DJ, Lipke ML, de Lore D, Swiedler SJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study. Clin Genet. 2009;77(5):492\u20138. doi: 10.1111\/j.1399-0004.2009.01324.x .","journal-title":"Clin Genet"},{"issue":"1","key":"344_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","volume":"109","author":"G Baldo","year":"2013","unstructured":"Baldo G, Mayer FQ, Martinelli BZ, de Carvalho TG, Meyer FS, de Oliveira PG, et al. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab. 2013;109(1):33\u201340. doi: 10.1016\/j.ymgme.2013.03.005 .","journal-title":"Mol Genet Metab"},{"issue":"60","key":"344_CR15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1126\/scitranslmed.3001380","volume":"2","author":"AD Dierenfeld","year":"2010","unstructured":"Dierenfeld AD, McEntee MF, Vogler CA, Vite CH, Chen AH, Passage M, et al. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med. 2010;2(60):60\u201389. doi: 10.1126\/scitranslmed.3001380 .","journal-title":"Sci Transl Med"},{"issue":"1","key":"344_CR16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ymgme.2009.08.008","volume":"99","author":"A Tylki-Szymanska","year":"2009","unstructured":"Tylki-Szymanska A, Rozdzynska A, Jurecka A, Marucha J, Czartoryska B. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase). Mol Genet Metab. 2009;99(1):10\u20137. doi: 10.1016\/j.ymgme.2009.08.008 .","journal-title":"Mol Genet Metab"},{"issue":"5","key":"344_CR17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10545-007-0551-9","volume":"30","author":"RS Arora","year":"2007","unstructured":"Arora RS, Mercer J, Thornley M, Tylee K, Wraith JE. Enzyme replacement therapy in 12 patients with MPS I-H\/S with homozygous p.Leu490Pro mutation. J Inherit Metab Dis. 2007;30(5):821. doi: 10.1007\/s10545-007-0551-9 .","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"344_CR18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","volume":"5","author":"NJ Terlato","year":"2003","unstructured":"Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient\u2019s genotype? A comprehensive review of the literature. Genet Med. 2003;5(4):286\u201394. doi: 10.1097\/01.GIM.0000078027.83236.49 .","journal-title":"Genet Med"},{"issue":"1","key":"344_CR19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10545-006-0237-8","volume":"29","author":"AT Anbu","year":"2006","unstructured":"Anbu AT, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis. 2006;29(1):230\u20131. doi: 10.1007\/s10545-006-0237-8 .","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0344-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T20:54:53Z","timestamp":1498251293000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ojrd.com\/content\/10\/1\/131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1186\/s13023-015-0344-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,7]]},"article-number":"131"}}